Compare DMRA & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMRA | TRIN |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2020 | 2020 |
| Metric | DMRA | TRIN |
|---|---|---|
| Price | $22.10 | $17.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $46.78 | $19.00 |
| AVG Volume (30 Days) | 478.7K | ★ 885.1K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 11.66% |
| EPS Growth | ★ 121.48 | N/A |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.35 |
| Revenue Next Year | N/A | $16.34 |
| P/E Ratio | ★ N/A | $12.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.50 | $14.13 |
| 52 Week High | $34.89 | $18.90 |
| Indicator | DMRA | TRIN |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 47.69 |
| Support Level | $18.03 | $16.69 |
| Resistance Level | $22.27 | $17.35 |
| Average True Range (ATR) | 1.83 | 0.35 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 30.13 | 31.80 |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.